• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News > Statement from Dr Luis Pizarro, Executive Director of DNDi, about the Princess of Asturias Award for International Cooperation > Page 11

Statement from Dr Luis Pizarro, Executive Director of DNDi, about the Princess of Asturias Award for International Cooperation

Home > News > Statement from Dr Luis Pizarro, Executive Director of DNDi, about the Princess of Asturias Award for International Cooperation > Page 11

Statement from Dr Luis Pizarro, Executive Director of DNDi, about the Princess of Asturias Award for International Cooperation

Mother and child smiling
1 Jun 2023
  • English
    • English
    • Español
    • Português
    • 日本語

‘It is a fantastic honour for DNDi to be the recipient of the prestigious Princess of Asturias Award. To find ourselves among such illustrious fellow laureates is truly an extraordinary privilege. We would like to thank the Jury and Fundación Princesa de Asturias for giving such outstanding visibility to the millions of people around the world who are neglected by traditional pharmaceutical research. We would also like to thank the Spanish Royal National Academy of Medicine for their support of our candidacy.

This exceptional award comes at a special time for our organization, which is marking its 20th anniversary this year. Together with our partners, we have developed 12 new treatments for the most neglected populations around the world, and we have demonstrated that an alternative, not-for-profit model of pharmaceutical research and development can save millions of lives.

We are particularly proud of the successful research programmes we have established with leading medical institutions in Spain and in Latin America – all essential partners in our work to discover and develop new medicines against devastating diseases, such as Chagas and leishmaniasis, that continue to cause immense suffering for millions of people.

We would like to thank all our partners and supporters, without whom we could not have made such progress. And we will continue to work together, particularly on infectious diseases that are sensitive to climate change, such as dengue, which is spreading fast to new areas, including in Latin America and Southern Europe, and for which, unfortunately, there is still no specific treatment.’

For any media request, please contact media@dndi.org

Photo credit: Ana Ferreira-DNDi

Spain Latin America Europe

Read, watch, share

Loading...
Lab activities
Press releases
18 Mar 2025

DNDi welcomes GHIT support for new collaboration with Shionogi to identify novel drug candidates for neglected Chagas disease

Nature India Logo
Viewpoints
8 Mar 2025

Women are poorly represented in clinical trials. That’s problematic

Nature India
Veja Saúde
Viewpoints
17 Feb 2025

Doença do sono derrotada: lições de uma bem-sucedida missão na África

Veja Saúde
Woman scientist with test tube
Publications
13 Feb 2025

Strategic Plan 2021-2028: Mid-Term Review

Women in rural setting
Press releases
13 Feb 2025

DNDi announces organizational strategy update and strengthened executive team

Statements
12 Feb 2025

DNDi statement on recent US government executive actions and the escalating retreat from global health and medical research

DNDi and African Union teams at the MoU signing
Press releases
10 Feb 2025

The African Union Commission Strengthens Collaboration with the Drugs for Neglected Diseases initiative

Statements
5 Feb 2025

DNDi interventions at the 156th Session of the WHO Executive Board

VIEW ALL

Help neglected patients

To date, we have delivered fourteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Youtube X-twitter Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license